News & Updates
New Studies Show MammaPrint® and BluePrint® Tests Provide Greater Clarity Regarding Risk of Breast Cancer Recurrence and Classifications for Treatment
PRESS RELEASE New Studies Show MammaPrint® and BluePrint® Tests Provide Greater Clarity Regarding Risk of Breast Cancer Recurrence and Classifications for Treatment BluePrint reclassified 85 percent of tumors identified as HER2-amplified by IHC/FISH to non-HER2 Read More
New Research to be Presented at SABCS 2018 Reinforces MammaPrint and BluePrint Testing to Guide Breast Cancer Treatment Management Decisions
PRESS RELEASE Agendia Announces New Research Reinforcing MammaPrint® and BluePrint® Testing to Guide Breast Cancer Treatment Management Decisions Across Different Patient Populations and Ages at the 2018 San Antonio Breast Cancer Symposium IRVINE, CA, AMSTERDAM, Read More
Oncology Consultants Joins Agendia’s FLEX Big Data Registry Study
PRESS RELEASE Oncology Consultants Join Agendia’s FLEX Big DataRegistry Study, Helping to Build a Unique Resource for Breast Cancer Research All Oncology Consultants practices participate in the initiative, matching full genome profiles with complete clinical Read More
Latest Results from the I-SPY 2 Trial at the EORTC-NCI-AACR Symposium Demonstrate Ability of MammaPrint® and BluePrint® to Predict Treatment Response in Breast Cancer Patients
PRESS RELEASE Latest Results from the I-SPY 2 Trial at the EORTC-NCI-AACR Symposium Demonstrate Ability of MammaPrint® and BluePrint® to Predict Treatment Response in Breast Cancer Patients New data from the trial shows that a Read More
